A blood test measuring phosphorylated tau-217 (p-tau217) may help identify older adults at high risk of developing cognitive impairment years before noticeable problems with memory and thinking emerge. In an international study of 2,684 people who had no cognitive impairment at enrollment, participants with very high levels of the biomarker had an estimated 38% probability of developing cognitive impairment within five years and 78% within 10 years. However, substantially less data were available for the longer-term estimate, making it less reliable.
The findings offer new evidence that blood biomarkers could help predict future cognitive problems in people who currently have no symptoms. The study was led by researchers at the Massachusetts General Brigham Neuroscience Institute, with teams from North America, Japan and Australia. The results were presented at the Alzheimer’s Association International Conference and published simultaneously in a journal.
Blood tests linked to future cognitive decline
The researchers focused on p-tau217, a blood biomarker associated with Alzheimer’s disease. A test that measures p-tau217 recently received federal approval, raising hopes that blood tests could make Alzheimer’s disease easier to detect. Important questions remain, however, including whether these tests can reliably predict which people with normal cognitive function will eventually develop symptoms.
To investigate this question, the researchers combined data from six observational studies and clinical trials conducted in North America, Japan and Australia. The studies included 2,684 older adults who showed no signs of cognitive impairment when they enrolled.
Participants provided blood samples that were analyzed for p-tau217. They also underwent positron emission tomography (PET) brain scans, which allowed the researchers to establish baseline measurements of brain health. Annual follow-up assessments tracked changes in memory, thinking and other cognitive abilities.
The combined dataset covered an unusually long period. Some participants had taken part in one of the studies as early as 2004, while the most recent follow-up assessment took place in 2025.
About 478 participants ultimately developed cognitive impairment. When the researchers compared those outcomes with the participants’ initial blood test results, they found a strong association between elevated p-tau217 levels and the likelihood of future cognitive problems.
Among participants with very high biomarker levels, the estimated probability of developing cognitive impairment within five years was 38%. After 10 years, the estimated probability rose to 78%. The researchers emphasized that considerably fewer observations were available beyond 10 years, so the longer-term predictions are less certain.
Predictive information beyond genetics and brain scans
One of the study’s key findings was that p-tau217 provided information about future cognitive decline beyond other established risk factors.
Even after the researchers accounted for amyloid-beta plaques—abnormal protein deposits in the brain that can be detected with PET imaging—p-tau217 remained significantly associated with cognitive impairment. Its predictive value also extended beyond known genetic risk factors such as APOE4.
The results suggest that a relatively simple blood test could eventually give doctors additional information when estimating an individual’s likelihood of developing cognitive impairment.
“This is an important step toward better understanding what p-tau217 can tell us about risk for cognitive impairment,” said lead author Dr. Rachel F. Buckley, a cognitive neuroscientist at the Massachusetts General Brigham Neuroscience Institute. “What really sets this study apart is that it estimates an individual’s level of risk for cognitive impairment. We harmonized the data across six cohorts, creating a large and diverse dataset, and yet we found consistent results that show how p-tau217 signals risk over time.”
Rather than simply identifying biological changes associated with Alzheimer’s disease, the study estimates how those changes may translate into a person’s probability of developing symptoms over a particular period.
Why routine testing is not yet recommended for healthy people
Despite the promising results, researchers caution that blood tests are not currently recommended for routine Alzheimer’s disease risk screening in people without symptoms.
One reason is that preventive treatments capable of changing the course of the disease have not yet been established for otherwise healthy people identified as being at high risk.
“There are still no disease-modifying treatments for people found to be at high risk of developing cognitive impairment from Alzheimer’s disease, so we do not recommend currently available blood tests for people who are asymptomatic,” said senior corresponding author Leisa Sperling, M.D., a neurologist at Massachusetts General Brigham Neuroscience. “Currently, our medical advice is the same regardless of test results: exercise regularly, maintain a healthy diet, and prioritize sleep and overall health.”
“However, the landscape of preventive care could change rapidly if ongoing trials of disease-modifying therapies prove beneficial,” Sperling added. “In the future, these tests could help identify patients who are most likely to benefit from these treatments. Our long-term goal is to get to the point where cholesterol tests predict heart attack risk.”
The study has several limitations. Although the researchers drew on multiple studies and geographic regions, the participants may not fully represent the broader population. This potential selection bias could affect how well the findings apply to other groups.
The analysis also focused on the risk of cognitive impairment over a relatively limited period, rather than estimating a person’s lifetime risk. Larger and more representative studies, along with longer follow-up periods, will be needed to confirm the results and improve the accuracy of individual risk estimates.
Could blood tests support Alzheimer’s prevention?
The greatest potential benefit of this approach could emerge if scientists develop treatments that slow or prevent Alzheimer’s-related cognitive decline before noticeable symptoms begin.
Several clinical trials are investigating whether disease-modifying therapies can benefit people who have biological signs of Alzheimer’s disease but do not yet have cognitive impairment. If these treatments prove effective, biomarkers such as p-tau217 could help identify the people most likely to benefit from early intervention.
Such an approach could bring Alzheimer’s prevention closer to cardiovascular prevention, in which cholesterol measurements help doctors estimate future heart attack risk and determine who may benefit from treatment.
For now, blood tests can help researchers identify people at high risk who may be suitable candidates for prevention studies.
“Now, p-tau217 can help identify people at high risk of future Alzheimer’s dementia for participation in prevention trials,” Sperling said. “As these trials progress, individualized estimates, including the prognostic value of the biomarkers, may guide earlier treatment and monitoring decisions.”
Authors, disclosures and funding
In addition to Sperling and Buckley, the Mass General Brigham authors were Diana L. Townsend, Colin J. Birkenbiel, Madison Kuppels, Gillian T. Coughlan, Mabel T. Seto, Jane A. Brown, Michael J. Properzi, Merle C. Honig, Annie Lee, Aaron P. Schulz, Jasmia Chatwal, Hyungsik Yang, Steven Arnold, Pia Kivisak, Brian Healy, Jorge Garcia Condado, Waiying Wendy Yau, Michelle Farrell, Rebecca E. Amarillio, Doren M. Lentz, Kathryn V. Papp and Keith A. Johnson. Additional authors were Brian D. James, Sid O’Bryant, Robert A. Risman, Melissa Petersen, Jessica ZK Caldwell, Toby Betthauser, Julie Elizabeth Omens, Maria Carrigan, Sterling C. Johnson, Oliver Langford, Ron Brookmeyer, Timothy J. Homan, Michael Donahue and Paul S. Eisen.
Buckley reported receiving grants from the National Institutes of Health (NIH) outside the submitted research. Sperling reported receiving grants from the NIH (A4; R01 AG063689, U24AG057437), the GHR Foundation and the Alzheimer’s Association during the study. She also reported consulting for AbbVie, AC Immune, Acumen, Alector, Apellis, Biohaven, Bristol Myers Squibb, Ionis, Immunobrain, Janssen, Novo Nordisk, Oligomerix, Prothena, Roche, Therini and Vaxxinity. Outside the submitted research, clinical trial funding will be provided through public-private partnerships with Eisai and Eli Lilly. Additional author disclosure information is available in the disclosure section of the paper.
The study was supported by the National Institutes of Health through grants R01AG079142, DP2AG082342, U01 AG024904, R01AG054073, R01AG058533, R01AG070862, P41EB015922, U19AG078109, R01AG027161, R01AG021155, P30AG062715, U19AG010483, R01AG063689, P01 AG036694, P41EB015896, S10RR021110, S10RR023401 and S10RR023043. Additional in-kind support came from Avid, Cogstate, Albert Einstein College of Medicine, Neurological Disorders Foundation and Meso Scale Diagnostics.
Source: www.sciencedaily.com


